Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

The Relapse Mechanisms and Genomic Landscape Differ in KMT2A -r Pediatric Leukemia in Relation to Relapse Time

Louise Ahlgren, Mattias Pilheden, Helena Sturesson, Varsha Singh, Qirui Zhang, Michael Walsh, Guangchun Song, Anders Castor, Cornelis Jan Pronk, Pauline Schneider, Ronald W. Stam, Gisela Barbany, Katja Pokrovskaja Tamm, Jonas Abrahamsson, Linda Fogelstrand, Olli Lohi, Jing Ma, Jinghui Zhang, Anna K. Hagstroem-Andersson

Blood (2023) 142 (Supplement 1): 2978.

https://doi.org/10.1182/blood-2023-185044

Published: 2023

Journal Articles

Genomic Determinants of Therapy Response in ETV6::RUNX1 Leukemia

Laura Oksa, Sanni Moisio, Khurram Maqbool, Hassan Foroughi-Asl, Roger Kramer, Atte Nikkilä, Kaisa Vepsäläinen, Jesus Duque-Afonso, Julia Hauer, Jessica Nordlund, Valtteri Wirta, Olli Lohi, Merja Heinäniemi

Blood (2023) 142 (Supplement 1): 2970.

https://doi.org/10.1182/blood-2023-188691

Published: 2023

Journal Articles

The Role of Small Nucleolar RNAs As Putative Biomarkers of Chemoresistance in Pediatric Acute Lymphoblastic Leukemia

Olga Krali, Anna Pia Enblad, Kristin Blom, Claes Andersson, Britt-Marie Frost, Josefine Palle, Arja Harila, Olli Lohi, Erik Forestier, Jukka Kanerva, Trond Flægstad, Ólafur G Jónsson, Kjeld Schmiegelow, Mats Heyman, Peter Nygren, Rolf Larsson, Gudmar Lönnerholm, Jessica Nordlund

Blood (2023) 142 (Supplement 1): 6064.

https://doi.org/10.1182/blood-2023-185687

Published: 2023

Journal Articles

The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia

Blood (2023) 141 (23): 2853–2866.

https://doi.org/10.1182/blood.2022019425

Published: 2023

Includes: Supplemental data

Journal Articles

Mechanistic Study of Wee1 Kinase Inhibition with AZD1775 Exposes Drug Targetable Vulnerabilities in Acute B-Lymphoblastic Leukemia

Alena Malyukova, Mari Lahnalampi, Ton Falqués, Petri Pölönen, Mikko Sipola, Juha Mehtonen, Susanna Teppo, Johanna Viiliäinen, Olli Lohi, Anna Hagstroem-Andersson, Merja Heinäniemi, Olle Sangfelt

Blood (2022) 140 (Supplement 1): 11576.

https://doi.org/10.1182/blood-2022-168684

Published: 2022

Journal Articles

Identification and Interpretation of Clinically Relevant Somatic Variants from Whole-Genome Sequencing Data

Khurram Maqbool, Hassan Hassan Foroughi-Asl, Ashwini Ashwini Jeggari, Vadym Ivanchuk, Jesper Eisfeldt, Annick Renevey, Keyvan Elhami, Chiara Rasi, Daniel Nilsson, Merja Heinäniemi, Olli Lohi, Valtteri Wirta

Blood (2022) 140 (Supplement 1): 13003–13004.

https://doi.org/10.1182/blood-2022-163295

Published: 2022

Journal Articles

Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia

Blood (2022) 140 (17): 1891–1906.

https://doi.org/10.1182/blood.2021015106

Published: 2022

Includes: Supplemental data

Journal Articles

The Molecular Landscape of KMT2A -Rearranged Leukemia from Infancy to Adulthood Reveals Age and Leukemia-Specific Mutational Patterns

Blood (2021) 138 (Supplement 1): 3479.

https://doi.org/10.1182/blood-2021-152082

Published: 2021

Journal Articles

Spatio-Temporal Clustering of Childhood Leukemia Relative to Population Mixing in Finland: A Nationwide Register-Based Study

Atte Nikkilä, MD, Jani Raitanen, MSc, Olli Lohi, MD PhD, Anssi Auvinen, MD PhD

Blood (2019) 134 (Supplement_1): 5070.

https://doi.org/10.1182/blood-2019-125930

Published: 2019

Journal Articles

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Lai N Chan, PhD, Mark A. Murakami, MDMA,MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, Seyedmehdi Shojaee, PhD, Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Arun P. Wiita, MD PhD, Shai Izraeli, MD, David M Weinstock, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3944.

https://doi.org/10.1182/blood-2019-130774

Published: 2019

Journal Articles

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Atte Nikkilä, MD, Olli Lohi, MD PhD, Ólafur Gísli Jónsson, MD PhD, Bendik Lund, MD PhD, Jonas Abrahamsson, Goda Elizabeta Vaitkeviciene, MD PhD, Kaie Pruunsild, MD, Mats Heyman, MD PhD, Hanne Vibeke Marquart, MD PhD, Kim Vettenranta, MD PhD, Kjeld Schmiegelow, MD PhD

Blood (2019) 134 (Supplement_1): 742.

https://doi.org/10.1182/blood-2019-122914

Published: 2019

Journal Articles

Immunogenomic Landscape of Hematological Malignancies

Olli Dufva, Petri Pölönen, MSc, Oscar Brück, MD, Mikko A Keränen, MD PhD, Juha Mehtonen, MSc, Sanna M. Siitonen, MD PhD, Suvi-Katri Leivonen, PhD, Leo Meriranta, MS, Sirpa Leppa, MD Prof, Matti Nykter, Olli Lohi, MD PhD, Merja Heinäniemi, PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 2596.

https://doi.org/10.1182/blood-2018-99-118335

Published: 2018

Journal Articles

Stat5 Feedback Control Switches MYC- and BCL6-Dependent Cell Fates in Normal and Transformed B Cells

Zhengshan Chen, MDPhD, Lai N Chan, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Cheryl L. Willman, MD, Markus Muschen, MDPhD

Blood (2017) 130 (Supplement 1): 1440.

https://doi.org/10.1182/blood.V130.Suppl_1.1440.1440

Published: 2017

Journal Articles

Genome-Wide Analysis of the Regulatory Landscape in Different Pre-B-ALL Subtypes

Mari Lahnalampi, MSc, Juha Mehtonen, MSc, Susanna Teppo, MSc, Saara Laukkanen, MSc, Laura Oksa, MSc, Markus Muschen, MD, Olli Lohi, MD PhD, Merja Heinäniemi, PhD

Blood (2017) 130 (Supplement 1): 3807.

https://doi.org/10.1182/blood.V130.Suppl_1.3807.3807

Published: 2017

Journal Articles

Pan-Hematopoietic Cancer Gene Expression Analysis Identifies Immunologically Active Acute Myeloid Leukemia Subtypes

Olli Dufva, Petri Pölönen, Mikko A Keränen, MD PhD, Thomas Liuksiala, Jake Lin, Juha Mehtonen, MSc, Sergei Häyrynen, Kirsi Granberg, PhD, Matti Nykter, PhD, Olli Lohi, Merja Heinäniemi, PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 1725.

https://doi.org/10.1182/blood.V128.22.1725.1725

Published: 2016

Journal Articles

In Silico and Ex Vivo Drug Screening Identifies Dasatinib as a Potential Targeted Therapy for T-ALL

Saara Laukkanen, Petri Pölönen, Toni Grönroos, Heikki Kuusanmäki, MSc, Caroline A Heckman, PhD, Mika Kontro, Merja Heinäniemi, Olli Lohi

Blood (2016) 128 (22): 4029.

https://doi.org/10.1182/blood.V128.22.4029.4029

Published: 2016

Journal Articles

Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments

Susanna Teppo, MSc, Juha Mehtonen, MSc, Samuli Eldfors, MSc, Caroline A Heckman, PhD, Markus Müschen, MD PhD, Merja Heinäniemi, PhD, Olli Lohi

Blood (2016) 128 (22): 4077.

https://doi.org/10.1182/blood.V128.22.4077.4077

Published: 2016

Journal Articles

Identification of Novel Drug Targets in T-Cell Acute Lymphoblastic Leukemia

Saara Laukkanen, Thomas Liuksiala, Matti Nykter, Merja Heinäniemi, Olli Lohi

Blood (2015) 126 (23): 3646.

https://doi.org/10.1182/blood.V126.23.3646.3646

Published: 2015

Journal Articles

Mapping the Gene Expression Diversity Across Hematological and Lymphoid Malignancies

Thomas Liuksiala, Kirsi Granberg, Sergei Häyrynen, Juha Mehtonen, Petri Pölönen, Susanna Teppo, MSc, Jake Lin, Saara Laukkanen, Patrick May, Matti Nykter, Merja Heinäniemi, Olli Lohi

Blood (2015) 126 (23): 4805.

https://doi.org/10.1182/blood.V126.23.4805.4805

Published: 2015

Journal Articles

Characterizing the Global Transcriptional Effects of TEL-AML1-Fusion in Childhood Acute Lymphoblastic Leukemia

Susanna Teppo, MSc, Kaisa J Teittinen, PhD, Toni Grönroos, MSc, Keijo Viiri, PhD, Minna Kaikkonen, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD

Blood (2014) 124 (21): 3794.

https://doi.org/10.1182/blood.V124.21.3794.3794

Published: 2014

NARROW

The Relapse Mechanisms and Genomic Landscape Differ in KMT2A -r Pediatric Leukemia in Relation to Relapse Time

Genomic Determinants of Therapy Response in ETV6::RUNX1 Leukemia

The Role of Small Nucleolar RNAs As Putative Biomarkers of Chemoresistance in Pediatric Acute Lymphoblastic Leukemia

The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia

Mechanistic Study of Wee1 Kinase Inhibition with AZD1775 Exposes Drug Targetable Vulnerabilities in Acute B-Lymphoblastic Leukemia

Identification and Interpretation of Clinically Relevant Somatic Variants from Whole-Genome Sequencing Data

Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia

The Molecular Landscape of KMT2A -Rearranged Leukemia from Infancy to Adulthood Reveals Age and Leukemia-Specific Mutational Patterns

Spatio-Temporal Clustering of Childhood Leukemia Relative to Population Mixing in Finland: A Nationwide Register-Based Study

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Immunogenomic Landscape of Hematological Malignancies

Stat5 Feedback Control Switches MYC- and BCL6-Dependent Cell Fates in Normal and Transformed B Cells

Genome-Wide Analysis of the Regulatory Landscape in Different Pre-B-ALL Subtypes

Pan-Hematopoietic Cancer Gene Expression Analysis Identifies Immunologically Active Acute Myeloid Leukemia Subtypes

In Silico and Ex Vivo Drug Screening Identifies Dasatinib as a Potential Targeted Therapy for T-ALL

Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments

Identification of Novel Drug Targets in T-Cell Acute Lymphoblastic Leukemia

Mapping the Gene Expression Diversity Across Hematological and Lymphoid Malignancies

Characterizing the Global Transcriptional Effects of TEL-AML1-Fusion in Childhood Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only